Filing Flows › Pacific Biosciences of California (PACB) › Q2 2026 › vs Q1 2026
Pacific Biosciences of California (PACB) Q2 2026 vs Q1 2026 (quarter over quarter)
Pacific Biosciences of California's revenue rose $1.8M (+5%) from $37.2M in Q1 2026 to $39.0M in Q2 2026. The biggest changes: Product revenue +$1.4M (+4%); Service and other revenue +$413K (+7%).
Pacific Biosciences of California, Q2 2026: revenue $39.0M (-2% year over year), operating margin -114.4%, net loss $44.7M, operating cash flow −$35.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Consumable revenue | $20.1M | $21.8M | −$1.7M | -8% |
| Instrument revenue | $12.8M | $9.7M | $3.1M | +32% |
| Product revenue | $33.0M | $31.5M | $1.4M | +4% |
| Service and other revenue | $6.1M | $5.6M | $413K | +7% |
| Revenue | $39.0M | $37.2M | $1.8M | +5% |
| Net loss | $44.7M | $8.3M | $36.5M | +441% |
| Costs & expenses | $83.7M | $45.7M | $38.0M | +83% |
| Operating costs | $83.6M | $45.5M | $38.1M | +84% |
| Income tax | $58K | $184K | −$126K | -68% |
| Cost of revenue | $26.4M | $24.3M | $2.0M | +8% |
| Operating cash sources | $47.2M | $52.4M | −$5.2M | -10% |
| Depreciation | $2.3M | $3.2M | −$899K | -28% |
| Share-based compensation | $9.3M | $4.5M | $4.8M | +108% |
| Cash used in operations | $35.6M | $44.7M | −$9.1M | -20% |
| Net loss absorbed | $44.7M | $8.3M | $36.5M | +441% |
| Working capital & other | $2.4M | $44.1M | −$41.7M | -94% |
Questions
How much did Pacific Biosciences of California's revenue grow quarter over quarter in Q2 2026?
Pacific Biosciences of California's revenue rose $1.8M (+5%) from $37.2M in Q1 2026 to $39.0M in Q2 2026.
What drove Pacific Biosciences of California's revenue change in Q2 2026?
Product revenue +$1.4M (+4%); Service and other revenue +$413K (+7%).